期刊名称：EXPERT OPINION ON ORPHAN DRUGS
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
EDITOR-IN-CHIEF: Prof. M Ian Phillips, Director of Center for Rare Disease Therapies, Keck Graduate Institute of Applied Life Sciences.
Commissioning Editor: Lizzie Howard
Production Manager: Jonathan Collard
ISSN: 2167-8707 (print), 2167-8707 (electronic)
Aims & Scope
Expert Opinion on Orphan Drugs is an international, peer-reviewed journal that covers all aspects of R&D on rare diseases and orphan drugs.
The Editors welcome:
- Reviews that focus on rare diseases or orphan drugs, and report on any of the following topics: diagnostics, pharmacogenomics and screening; prevalence and epidemiology (with particular attention to regional variations); drug development; lead generation and discovery; early or late phase clinical trials; regulatory issues; post-marketing safety; treatment outcomes.
- Drug Evaluations specifically reviewing the pharmacological properties; clinical potential/clinical efficacy; safety and, if applicable, HE/OR data on a particular orphan drug.
- Original Research papers reporting the results of early or late stage clinical investigations or HE/OR data on orphan drugs and studies in the treatment of rare diseases.
- Editorials, commentaries and meeting-highlights papers covering topics in rare diseases.
Instructions to Authors
Instructions for authors can be found at the links below:
To submit a manuscript click here.
Please complete and return a disclosure form with your submission.
For full details of our editorial policies, including NIH-funded papers, please refer to our policy document and resources for authors.
Original research and other unsolicited articles
The Commissioning Editor, under the advice of the Editorial Board, solicits articles published in Expert Opinion on Orphan Drugs. However, the submission of Original Research and other unsolicited articles is welcomed, for which we offer the following service options:
- FastTrack is the ultra-rapid publication service option offering prioritised peer review and expedited publication of manuscripts (submission to online publication in 5-7 weeks).
- RapidTrack is the other prioritised option, offering submission to online publication in 10-12 weeks. A publication support fee is required for these service levels.
- StandardTrack offers a non-prioritised service, where accepted manuscripts achieve submission to online publication in up to 20 weeks. There are no publication fees for this service.
Pre-submission contact
Expert Opinion on Orphan Drugs welcomes authors contacting the Editorial Office ahead of formal submission and specially encourages prior contact for FastTrack submissions where a particular publication deadline is desired. If you are interested in submitting an article, please contact Lizzie Howard.
Peer review
All manuscripts are subject to confidential and anonymous (double-blinded) peer review by at least two independent referees. Comments remain confidential and are shared only with the corresponding author or submitting party.
For our peer review guidelines, please click here.
For Original Research peer review guidelines, please click here.
CrossCheck
Please note that your paper may be sent to CrossCheck for aplagiarism check. Clickhere for more information
Read More: http://informahealthcare.com/page/eod/Description
Instructions for authors can be found at the links below:
To submit a manuscript click here.
Please complete and return a disclosure form with your submission.
For full details of our editorial policies, including NIH-funded papers, please refer to our policy document and resources for authors.
Original research and other unsolicited articles
The Commissioning Editor, under the advice of the Editorial Board, solicits articles published in Expert Opinion on Orphan Drugs. However, the submission of Original Research and other unsolicited articles is welcomed, for which we offer the following service options:
- FastTrack is the ultra-rapid publication service option offering prioritised peer review and expedited publication of manuscripts (submission to online publication in 5-7 weeks).
- RapidTrack is the other prioritised option, offering submission to online publication in 10-12 weeks. A publication support fee is required for these service levels.
- StandardTrack offers a non-prioritised service, where accepted manuscripts achieve submission to online publication in up to 20 weeks. There are no publication fees for this service.
Pre-submission contact
Expert Opinion on Orphan Drugs welcomes authors contacting the Editorial Office ahead of formal submission and specially encourages prior contact for FastTrack submissions where a particular publication deadline is desired. If you are interested in submitting an article, please contact Lizzie Howard.
Peer review
All manuscripts are subject to confidential and anonymous (double-blinded) peer review by at least two independent referees. Comments remain confidential and are shared only with the corresponding author or submitting party.
For our peer review guidelines, please click here.
For Original Research peer review guidelines, please click here.
CrossCheck
Please note that your paper may be sent to CrossCheck for aplagiarism check. Clickhere for more information.
Instructions to Authors
Guidelines for Original Research (EOOD).pdf
Editorial Board
Editorial Staff
Please contact Lizzie Howard with any queries regarding the journal.
Editor in Chief:
M. Ian Phillips, Director of the Center for Rare Disease Therapies, Keck Graduate Institute
Editorial Board:
Sabina Antoniu, Pulmonary Disease Division, University of Medicine and Pharmacy, Romania
Martin Braddock, Global Medicines Development, AstraZeneca R&D, UK
Maria Luisa Brandi, Unit of Bone and Mineral Metabolism, University of Florence, Italy
John Forman, Executive Director, New Zealand Organisation for Rare Disorders (NZORD), New Zealand
Stephen Groft, Director, Office of Rare Diseases, National Institutes of Health, USA
Aaron S. Kesselheim, Harvard Medical School and Brigham and Women's Hospital, USA
Stephen Kingsmore, Center for Pediatric Genomic Medicine, Children's Mercy Hospitals and Clinics, USA
Alex MacKenzie, Pediatrics, CHEO, University of Ottawa, Canada
Maria Mavris, EURORDIS - European Organisation for Rare Diseases, France
Daniel O'Connor, Medicines and Healthcare products Regulatory Agency, UK
Manuel Posada, Director, Research Institute for Rare Diseases, Instituto de Salud Carlos III, Spain
Peter L. Saltonstall, President and CEO, National Organization for Rare Disorders (NORD), USA
E Tsiridis, Academic Department of Trauma and Orthopaedics, University of Leeds, UK
|
